Skip to main content

Table 1 Circulating tumor cell status in relation to patient characteristics

From: Biomarkers characterization of circulating tumour cells in breast cancer patients

 

CTC+, number (percentage)

CTC-, number (percentage)

Pvalue (χ2)

Age, years

   

   ≤ 50

14 (41.2)

20 (58.8)

 

   > 50

32 (50)

32 (50)

NS

Histology

   

   Ductal

40 (47)

45 (53)

 

   Others

6 (46.2)

7 (53.8)

NS

Clinical tumor size

   

   ≤ 2 cm

25 (54.3)

21 (45.7)

 

   > 2-5 cm

15 (39.5)

23 (60.5)

 

   > 5 cm

6 (42.9)

8 (57.1)

NS

Clinical nodal status

   

   cN0

28 (47.5)

31 (52.5)

 

   cN+

11 (34.4)

21 (65.6)

NS

   Unknown

4 (57.1)

3 (42.9)

 

Grade

   

   I

8 (38.1)

13 (61.9)

 

   II

15 (44.1)

19 (55.9)

 

   III

20 (55.5)

16 (44.5)

 

   Unknown

3 (42.9)

4 (57.1)

NS

Hormonal status

   

   HR+

35 (46.7)

40 (53.3)

 

   HR-

11 (47.8)

12 (52.2)

NS

HER2 status

   

   HER2+

3 (21.4)

11 (78.6)

 

   HER2-

43 (51.2)

41 (48.8)

0.046

p53 status

   

   p53+

26 (51)

25 (49)

 

   p53-

7 (50)

7 (50)

 

   Unknown

13 (39.4)

20 (60.6)

NS

Ki-67 percentage

   

   ≤ 14%

20 (52.6)

18 (47.4)

 

   > 14%

26 (43.3)

34 (56.7)

NS

  1. HR+ indicates hormone receptor-positive: estrogen receptor-positive/progesterone receptor-positive (ER+/PR+), ER+/PR-, or ER-/PR+. HR- indicates hormone receptor-negative. A total of 98 patients were included in this study. Information on clinical nodal status was available in 91 out of 98 (92.8%) patients and information on p53 status was available in 65 out of 98 (66.3%) patients at the time of study analysis. P values were determined by chi-squared tests. All statistical tests were two-sided. CTC, circulating tumor cell; HER2, human epidermal growth receptor 2; NS, not significant.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us